Renovorx Stock Today
| RNXT Stock | USD 1.29 0.08 6.61% |
Performance9 of 100
| Odds Of DistressOver 70
|
RenovoRx is selling for under 1.29 as of the 23rd of November 2024; that is 6.61 percent increase since the beginning of the trading day. The stock's last reported lowest price was 1.21. RenovoRx has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for RenovoRx are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of October 2024 and ending today, the 23rd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of August 2021 | Category Healthcare | Classification Health Care |
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. Renovorx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 24 M outstanding shares of which 71.85 K shares are at this time shorted by private and institutional investors with about 3.43 trading days to cover. More on RenovoRx
Moving against RenovoRx Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
RenovoRx Stock Highlights
| Secretary CEO | Shaun Bagai | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRenovoRx can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand RenovoRx's financial leverage. It provides some insight into what part of RenovoRx's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
RenovoRx (RNXT) is traded on NASDAQ Exchange in USA. It is located in 4546 El Camino Real, Los Altos, CA, United States, 94022 and employs 8 people. RenovoRx is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 29.04 M. RenovoRx conducts business under Biotechnology sector and is part of Health Care industry. The entity has 24 M outstanding shares of which 71.85 K shares are at this time shorted by private and institutional investors with about 3.43 trading days to cover.
RenovoRx currently holds about 10.77 M in cash with (10.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.19.
Check RenovoRx Probability Of Bankruptcy
Ownership AllocationRenovoRx owns a total of 24 Million outstanding shares. Roughly 89.92 pct. of RenovoRx outstanding shares are held by general public with 1.9 % owned by insiders and only 8.18 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check RenovoRx Ownership Details
RenovoRx Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Tower Research Capital Llc | 2024-06-30 | 7.4 K | |
| Ubs Group Ag | 2024-06-30 | 1.3 K | |
| Royal Bank Of Canada | 2024-06-30 | 203 | |
| Bank Of America Corp | 2024-06-30 | 182 | |
| Family Firm Inc | 2024-09-30 | 0.0 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Renaissance Technologies Corp | 2024-09-30 | 0.0 | |
| Adar1 Capital Management Llc | 2024-06-30 | 355.2 K | |
| Geode Capital Management, Llc | 2024-06-30 | 143.9 K | |
| Watch Point Trust Co | 2024-09-30 | 97.2 K | |
| Millennium Management Llc | 2024-06-30 | 86.3 K |
RenovoRx Historical Income Statement
RenovoRx Stock Against Markets
RenovoRx Corporate Management
| CGMA CPA | Controller VP | Profile | |
| Ronald CPA | VP Controller | Profile | |
| James Ahlers | Chief Officer | Profile | |
| Leesa Gentry | Senior Operations | Profile | |
| Angela Nelms | Chief Officer | Profile | |
| Ryan Witt | Senior Partnerships | Profile | |
| Ramtin MD | Chairman Founder | Profile |
Additional Tools for RenovoRx Stock Analysis
When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.